The Alvimedica Cre8™ EVO DES resulted superior to Onyx™ DES in the independent SUGAR RCT with regard to TLF at 1 year (7.2% Cre8™ EVO vs. 10.9% Onyx™; p superiority = 0.030).
A global manufacturer of unique interventional medical devices, harnessing the power of innovation to improve our patient’s quality of life. We tackle today’s toughest patients clinical conditions by creating innovative products.
We create the highest quality products, trusted by leading professionals around the world.
Our driving passion is to improve the quality of life through innovative technology, creating a better future by investing in both clinical research and product development.
Alvimedica is committed to improving patient outcomes, as well as tackling global issues such as Diabetes, which we are 100% committed to defeating.
Diabetes is a number of diseases that involve
problems with hormone insulin.